Questions without easy answers are often ones that provoke change. This is certainly true of questions about access to medicines, which have been at the heart of the EU health debate for the past year or more. Are all the key players acting in a way that allows patients to get access to essential and innovative medicines when they need them? In a policy context, is there anything that the EU can – or even, should – do to help improve patient access to medicines in Europe?